Vistagen Therapeutics, Inc. (VTGN)

In November 2025, Vistagen reported its Q2 2026 earnings. In December 2025, the company's stock plunged after its PALISADE-3 Phase 3 study failed, and Vistagen announced cash preservation measures. In February 2026, Vistagen reported its Q3 2026 earnings and received a Nasdaq non-compliance notice. In March 2026, Vistagen reduced its workforce by approximately 20% and announced participation in investor conferences. In April 2026, Vistagen received FDA approval to proceed with Phase 2 clinical development for refisolone nasal spray. In May 2026, Vistagen completed the last patient visit in the PALISADE-4 Phase 3 clinical trial, with topline results expected in the second quarter of 2026. The stock price as of May 6, 2026, was $0.61 per share, a 74% decline over the past year.

As a clinical-stage biopharmaceutical company, Vistagen Therapeutics, Inc. does not experience traditional demand seasonality for its products, as they are not yet commercially available. Demand for its potential future products will be driven by medical needs and regulatory approvals rather than seasonal consumer patterns. Stock price seasonality reflects investor behavior and market trends rather than product demand.

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for psychiatric and neurological disorders, operating within the Biotechnology industry. Vistagen leverages a deep understanding of nose-to-brain neurocircuitry to develop a new class of intranasal product candidates called pherines, designed to rapidly activate brain neurocircuitry through the olfactory system. The company's pipeline includes Fasedienol (PH94B) for social anxiety disorder, Itruvone (PH10) for depression disorders, AV-101 for Major Depressive Disorder and neuropathic pain, Refisolone (PH80) for vasomotor symptoms due to menopause, PH15 for cognition improvement and PH284 for cancer cachexia and wasting syndrome.

Vistagen Therapeutics, Inc. is headquartered in South San Francisco, California, United States, with clinical development and commercialization efforts primarily focused in North America. The company has a licensing agreement with Yuhan Corporation for AV-101 in South Korea and retains exclusive rights to develop and commercialize Fasedienol in markets outside of Greater China, South Korea, and Southeast Asia.

Vistagen Therapeutics' reputation has been influenced by both positive recognition and legal challenges. The company received a "2025 Platinum Bell Seal for workplace mental health." However, the company has also faced negative publicity, including a class-action lawsuit and the failure of the PALISADE-3 trial, which could have negatively impacted its brand reputation.

Vistagen Therapeutics, Inc. has a diverse ownership structure, with retail investors holding approximately 49% of the company. Institutional investors collectively hold 11,441,614 shares, with major owners including Orbimed Advisors Llc and Vanguard Group Inc. The largest individual/insider shareholder is Venrock Healthcare Capital Partners II LP, owning 52.09% of the company.